



Allergologia et immunopathologia

www.elsevier.es/ai



RESEARCH LETTER

Anaphylaxis to levofloxacin

To the Editor,

A 55-year-old woman without prior history of drug allergy, scheduled for cataract surgery, received oral levofloxacin (500mg) for antibiotic prophylaxis. Within minutes after levofloxacin intake, she experienced sneezing and palmo-plantar pruritus followed by generalised pruritus along with facial, lingual and pharyngeal angio-oedema and subsequent dyspnoea. These clinical signs were followed by digestive (i.e. vomiting, abdominal pain and diarrhoea) and cutaneous (generalised erythema) signs. Surgery was postponed. Clinical signs resolved within hours with hydrocortisone and dexchlorpheniramine. Further clinical outcome was uneventful.

Plasma histamine (70 nmol l^{-1} , $N < 10$) and serum tryptase ($32.7 \mu\text{g l}^{-1}$, $N < 13.5$) measured 75 min after the clinical reaction, showed increased concentrations. Basal tryptase ($3.4 \mu\text{g l}^{-1}$) measured two days after remained unchanged. With the patient's consent, allergological assessment was performed four weeks later. Prick-test (PT) at 10^{-2} dilution (0.05 mg/ml) was positive in response to levofloxacin. Cross-reactivity was found with ofloxacin through PT (10^{-1} dilution: 0.5 mg/ml) while skin testing remained negative in response to ciprofloxacin (i.e. PT stock solution: 2 mg/ml and intradermal tests up to 10^{-1} dilution: 0.2 mg/ml). Pefloxacin was not skin-tested. IgE-mediated levofloxacin-induced allergy, with cross-reactivity to ofloxacin and absence of cross-reactivity to ciprofloxacin, was therefore confirmed on the basis of the typical clinical history, increased tryptase level along with skin test results. With the patient's informed consent and under medical supervision, graded drug challenge using ciprofloxacin at increasing intravenous doses (cumulative dose: 150 mg) was performed¹ and remained negative, therefore excluding ciprofloxacin sensitisation.

Although rare, immediate hypersensitivity to quinolones may be due to direct pharmacological effects (i.e. histamine release) or IgE-mediated mechanism.^{2,3} Ciprofloxacin is frequently involved as it is the most commonly quinolone used.³ The diagnostic values of skin tests in quinolone allergy remain controversial. Contradictory results regarding the sensitivity of skin tests in quinolone allergy have been reported, whereas in controls, positive skin tests were

attributed to direct mast cell activation.⁴ Thus, low non-irritating intradermal tests concentrations for quinolones were proposed with subsequent low sensitivity of intradermal tests to these drugs.⁴ Others suggest using specific Sepharose-RIA assay to prove quinolone IgE-mediated hypersensitivity.³ However, a few in vitro studies showed that the sensitivity of the RIA-assay and the basophil activation test differed according to the fluoroquinolone tested⁵ while these results^{3,5} were, in the meantime, not compared to the in vivo skin tests results.

Fluoroquinolones are synthetic derivatives of nalidixic acid with a common core of a bicyclic ring structure and cross-reactivity, related to the structure of the molecules, seems to be common.^{3,4} Our patient showed cross-reactivity to ofloxacin as levofloxacin is the active L-isomer of ofloxacin. Both are fluorinated 4-quinolones containing a pyridobenzoxazine ring from positions 1 to 8 of the basic ring structure. Side chain reactivity to these sites alone might explain cross-reactivity to ofloxacin and lack of cross-reactivity to ciprofloxacin, as ciprofloxacin is devoided of any side chain in this position.² However, there is no general rule to predict cross-reactivity between quinolones. Thus to be complete during the diagnostic approach of quinolone-induced IgE-mediated anaphylaxis, investigation for cross-reactivity with the other commercialised quinolones should be performed in order to identify safe alternative regimens (i.e. negative skin-tested quinolones).

Intravenous challenge with ciprofloxacin remained uneventful and thus excluded cross-reactivity with related drugs (i.e. levofloxacin and ofloxacin). This allowed providing a safe alternative in cases of fluoroquinolones requirement in our patient. This finding contrasts with other reports suggesting strict avoidance of all quinolones in patients with quinolone-allergy.^{3,6}

In conclusion, skin test might be a useful tool to prove quinolone-induced IgE-mediated hypersensitivity, whereas the challenge test might help to confirm the negative predictive values of skin tests to quinolones and thus authorise a safe alternative.

Funding

Support was solely provided from institutional and/or departmental resources.

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans for this investigation.

Confidentiality of data. The authors declare that no patient data appears in this article.

Right to privacy and informed consent. The authors declare that no patient data appears in this article.

References

1. Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. *Allergy*. 2003;58:854–63.
2. Chang B, Knowles SR, Weber E. Immediate hypersensitivity to moxifloxacin with tolerance to ciprofloxacin: report of three cases and review of the literature. *Ann Pharmacother*. 2010;44:740–5.
3. Manfredi M, Severino M, Testi S, Macchia D, Ermini G, Pichler WJ, et al. Detection of specific IgE to quinolones. *J Allergy Clin Immunol*. 2004;113:155–60.
4. Campi P, Manfredi M, Severino M. IgE-mediated allergy to pyrazolones, quinolones and other non beta-lactam antibiotics. In: Pichler WJ, editor. *Drug hypersensitivity*. Basel: Karger Medical and Scientific Publishers; 2007. p. 216–32.
5. Aranda A, Mayorga C, Ariza A, Dona I, Rosado A, Blanca-Lopez N, et al. *In vitro* evaluation of IgE-mediated hypersensitivity reactions to quinolones. *Allergy*. 2010;66:247–54.
6. Gonzalez I, Lobera T, Blasco A, del Pozo MD. Immediate hypersensitivity to quinolones: moxifloxacin cross-reactivity. *J Investig Allergol Clin Immunol*. 2005;15:146–9.

P. Dewachter^{a,*}, C. Mouton-Faivre^b

^a *Université Paris-Descartes, INSERM U970, Assistance Publique Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Service d'Anesthésie-Réanimation et SAMU de Paris, Paris, France*

^b *Pôle d'Anesthésie-Réanimation Chirurgicale, CHU Hôpital Central, Nancy, France*

* Corresponding author.

E-mail address: pascale.dewachter@yahoo.fr (P. Dewachter).